These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 31595147)

  • 41. Autophagy Regulatory Genes MET and RIPK2 Play a Prognostic Role in Pancreatic Ductal Adenocarcinoma: A Bioinformatic Analysis Based on GEO and TCGA.
    Li X; Li Z; Zhu H; Yu X
    Biomed Res Int; 2020; 2020():8537381. PubMed ID: 33204717
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Integrate analysis of the promote function of Cell division cycle-associated protein family to pancreatic adenocarcinoma.
    Xing C; Wang Z; Zhu Y; Zhang C; Liu M; Hu X; Chen W; Du Y
    Int J Med Sci; 2021; 18(3):672-684. PubMed ID: 33437202
    [No Abstract]   [Full Text] [Related]  

  • 43. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.
    Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Han C; Zhu G; Su H; Han Q; Chen Z; Huang J; Gong Y; Ruan G; Ye X; Peng T
    Cancer Med; 2020 Feb; 9(3):859-871. PubMed ID: 31808619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery.
    Sergeant G; van Eijsden R; Roskams T; Van Duppen V; Topal B
    BMC Cancer; 2012 Nov; 12():527. PubMed ID: 23157946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.
    Lu H; Niu F; Liu F; Gao J; Sun Y; Zhao X
    Cancer Med; 2017 Jun; 6(6):1181-1191. PubMed ID: 28440066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
    Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unraveling pancreatic ductal adenocarcinoma immune prognostic signature through a naive B cell gene set.
    Zhang S; Ta N; Zhang S; Li S; Zhu X; Kong L; Gong X; Guo M; Liu Y
    Cancer Lett; 2024 Jul; 594():216981. PubMed ID: 38795761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel methylation signature predicts inferior outcome of patients with PDAC.
    Gu M; Sun J; Zhang S; Chen J; Wang G; Ju S; Wang X
    Aging (Albany NY); 2021 Jan; 13(2):2851-2863. PubMed ID: 33550277
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia.
    Ren M; Feng L; Zong R; Sun H
    World J Surg Oncol; 2023 Aug; 21(1):257. PubMed ID: 37605192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma.
    Sandhu V; Labori KJ; Borgida A; Lungu I; Bartlett J; Hafezi-Bakhtiari S; Denroche RE; Jang GH; Pasternack D; Mbaabali F; Watson M; Wilson J; Kure EH; Gallinger S; Haibe-Kains B
    JCO Clin Cancer Inform; 2019 May; 3():1-16. PubMed ID: 31070984
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma.
    Huang H; Zou Y; Zhang H; Li X; Li Y; Deng X; Sun H; Guo Z; Ao L
    Transl Res; 2020 May; 219():30-44. PubMed ID: 32119844
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of New Potential Targets for Pancreatic Ductal Adenocarcinoma by Integrated Bioinformatic Analysis.
    Li R; Yang T; Ren KE; Li J; Nagakawa Y; Zeng Y; Natsuyama Y; Yi SQ
    Anticancer Res; 2024 Oct; 44(10):4233-4250. PubMed ID: 39348994
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value.
    Namkung J; Kwon W; Choi Y; Yi SG; Han S; Kang MJ; Kim SW; Park T; Jang JY
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1160-7. PubMed ID: 26644397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.
    Stratford JK; Bentrem DJ; Anderson JM; Fan C; Volmar KA; Marron JS; Routh ED; Caskey LS; Samuel JC; Der CJ; Thorne LB; Calvo BF; Kim HJ; Talamonti MS; Iacobuzio-Donahue CA; Hollingsworth MA; Perou CM; Yeh JJ
    PLoS Med; 2010 Jul; 7(7):e1000307. PubMed ID: 20644708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.
    Tian X; Zhu X; Yan T; Yu C; Shen C; Hu Y; Hong J; Chen H; Fang JY
    Mol Oncol; 2017 Nov; 11(11):1544-1560. PubMed ID: 28796930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genomic relevance of FGF14 and associated genes on the prognosis of pancreatic cancer.
    Raja A; Malik MFA; Haq F
    PLoS One; 2021; 16(6):e0252344. PubMed ID: 34061869
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Deciphering fatty acid biosynthesis-driven molecular subtypes in pancreatic ductal adenocarcinoma with prognostic insights.
    Xu J; Liu M; Xue J; Lu P
    Cell Oncol (Dordr); 2024 Aug; 47(4):1475-1491. PubMed ID: 38753153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 59. Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma.
    Cai W; Bao W; Chen S; Yang Y; Li Y
    Cancer Cell Int; 2021 Dec; 21(1):698. PubMed ID: 34930261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overexpression of MYEOV predicting poor prognosis in patients with pancreatic ductal adenocarcinoma.
    Tang R; Ji J; Ding J; Huang J; Gong B; Zhang X; Li F
    Cell Cycle; 2020 Jul; 19(13):1602-1610. PubMed ID: 32420813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.